Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Minister-backed Panel to Propose Policies to Promote Drug Discovery
September 3, 2001
- Antacids Are Most Expensive in Tokyo: Inter-city Comparison of OTC Drug Prices
September 3, 2001
- PMSB Considers Introduction of Drug Master File System
September 3, 2001
- Kirin-do to Strengthen Dispensing Function
September 3, 2001
- ADR Reports on 6 Drugs Including Temocapril HCl Published
September 3, 2001
- Jovi to Tie Up with CGC Japan
September 3, 2001
- 10 New Ingredients Added to NHI Price List
September 3, 2001
- Seijo to Tie Up with Fuji Yakuhin, Mine Yakuhin
September 3, 2001
- Time Clock from Development to Approval to Be Shortened to within 5 Years?
September 3, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 3, 2001
- BUSINESS NEWS IN BRIEF
September 3, 2001
- Korosho to Present Healthcare Reform Proposals in September
September 3, 2001
- Takeda, Bayer Decide to Recall Cerivastatin in Japan
September 3, 2001
- Bungyo Rate Increased to 43.5% in April: JPA
September 3, 2001
- Takeda Withdraws Calan
September 3, 2001
- JMA Research Institute Proposes Basic Policy for e-health
September 3, 2001
- Fukujin Ties Up with Kobayashi Daiyakubo
September 3, 2001
- Employees' Health Insurance Societies Have Assets of \5.2 Trillion: JMA
September 3, 2001
- Takeda Enters Top 10: Corporate Income Ranking
September 3, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 3, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…